Raises 2026 adjusted EPS guidance to at least $30.35
Cigna reported a strong Q1 2026 with EPS of $7.79, leading to an increase in full-year guidance to at least $30.35. The company announced strategic portfolio shifts, including exiting the individual exchange business and initiating a strategic review for eviCore, to focus on core growth platforms like specialty care and the new PBM model. Cigna's Q1 EPS of $7.79 was strong, driven by excellent performance in specialty and care services (20% growth) and Cigna Healthcare (18% growth).
Buzzberg readRaises 2026 adjusted EPS guidance to at least $30.35Cigna reported a strong Q1 2026 with EPS of $7.79, leading to an increase in full-year guidance to at least $30.35. The company announced strategic portfolio shifts, including exiting the individual exchange business and initiating a strategic review for eviCore, to focus on core growth platforms like specialty care and the new PBM model. Cigna's Q1 EPS of $7.79 was strong, driven by excellent performance in specialty and care services (20% growth) and Cigna Healthcare (18% growth).Read full analysisCollapse analysis
Cigna reported a strong Q1 2026 with EPS of $7.79, leading to an increase in full-year guidance to at least $30.35. The company announced strategic portfolio shifts, including exiting the individual exchange business and initiating a strategic review for eviCore, to focus on core growth platforms like specialty care and the new PBM model. Cigna's Q1 EPS of $7.79 was strong, driven by excellent performance in specialty and care services (20% growth) and Cigna Healthcare (18% growth).
Full-year 2026 EPS guidance raised to at least $30.35, reflecting confidence in sustained performance.
Company announced exit from individual exchange business and strategic review of eviCore, focusing resources on core platforms like specialty care, PBM, and employer health.
The rollout of the new 'Signature' rebate-free PBM model is progressing well, with strong client interest and a successful 2027 selling season.
Revenue$68.494B
-5% QoQ
EPS$7.79
-4% QoQ
Gross margin9.45%
reported
Op margin3.44%
reported
What changed this quarter
01
Guidance
Raises 2026 adjusted EPS guidance to at least $30.35
Guidance tone
02
Pharmacy
New rebate-free pharmacy model Signature to be standard by 2028
Cigna's Q1 EPS of $7.79 was strong, driven by excellent performance in specialty and care services (20% growth) and Cigna Healthcare (18% growth).
03
Portfolio
Planning to exit individual exchange business at end of 2026
Full-year 2026 EPS guidance raised to at least $30.35, reflecting confidence in sustained performance.
04
Portfolio
Initiating strategic review of alternatives for eviCore
Company announced exit from individual exchange business and strategic review of eviCore, focusing resources on core platforms like specialty care, PBM, and employer health.
AI, capex & demand read
AI
Platform & monetization
Management highlighted broad application of data, advanced analytics, and AI across its businesses to improve affordability, personalization, and customer experience, citing examples such as predictive high-cost claimant models, agentic AI in specialty pharmacy, and AI-driven contact center reductions. They are investing in AI as a core enabler but do not use AI for clinical decision-making.
Demand
Bookings & conversion
Management is raising full-year guidance due to strong first-quarter performance, particularly in specialty care and pharmacy, indicating a confident outlook for the rest of the year.
Capex
Investment and capacity
No explicit capital expenditure figures were provided, but management noted investments in the new rebate-free pharmacy model (Signature) as a key driver of near-term earnings headwinds, with such investments ramping through the year.
Tone · Confident
Management expressed positive forward-looking signals, raised full-year EPS guidance, and emphasized strong market reception to new initiatives like Signature, despite acknowledging some headwinds from portfolio reshaping and investments.
Supply-chain alpha
A1
Cigna's specialty and care services business grew 20% in Q1, driven by biosimilar and specialty generic adoption, indicating a strong secular tailwind in the specialty pharmacy space.
“This was driven by the strength of our specialty and care services businesses, which delivered adjusted earnings growth of 20% in the quarter”
Evernorth's NCI line item increased due to a new joint venture with a large client, with economics passed back to the client, highlighting a trend of health plans sharing PBM economics to secure renewals.
“the growth in NCI was primarily driven by a new joint venture with one of our largest clients, and the additional economics are passed back as part of the previously discussed renewals”
The exit from the individual exchange business and the strategic review of eviCore indicate a sharpened focus on core platforms like specialty care and PBM, potentially freeing up capital and management time for these high-growth areas.
“we have decided to initiate a strategic review of alternatives for eviCore”